The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.
Blueprint Medicines: Q3 Earnings Snapshot
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023, the Compensation Committee of Blueprint...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective September 1, 2023, the Compensation Committee of Blueprint...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint...
The company had generally improved earnings.
Blueprint Medicines: Q2 Earnings Snapshot
/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the second quarter ended...
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective July 1, 2023, the Compensation Committee of Blueprint...
Two mid-cap drugmakers stand out as logical targets for AbbVie.